ClinicalTrials.gg
CompletedNCT07241949Updated Nov 19, 2026

External Oblique Intercostal Block (EOICB) for Laparoscopic Cholecystectomy

An interventional study of Paravertebral Block (PVB) and External Oblique Intercostal Block (EOI Block) in Postoperative Pain, Laparoscopic Cholecystectomy and Paravertebral Block, sponsored by Cukurova University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Cukurova University · Not applicable, Interventional, and Treatment

How we know

Updated Nov 19, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
151
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies in Pain, Postoperative by Cukurova University — 4 open to participants now, 4 under way, none of them phase 3. Pain, Postoperative · Cukurova University.

Enrollment
2nd of 33
151 · median 60
Started
2025
with 1 other
No phase
20 of 33
4 open now
Registered
31st of 33
by date

Among the 33 studies in Pain, Postoperative by Cukurova University, this one is the 2nd largest by enrollment, is one of 2 that started in 2025, is one of 20 with no phase, and was the 31st registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

4 of the 33 studies in Pain, Postoperative by Cukurova University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Pain, Postoperative by Cukurova University, or all of them as a file.
02

Study summary

This single-center, prospective, randomized controlled trial aims to compare the effects of paravertebral block (PVB), external oblique intercostal (EOI) block, and intravenous patient-controlled analgesia (PCA) with tramadol on postoperative pain and opioid consumption in patients undergoing elective laparoscopic cholecystectomy. The primary endpoint is total tramadol consumption within 24 hours postoperatively. Secondary outcomes include pain scores, additional analgesic use, incidence of nausea/vomiting, mobilization time, and length of hospital stay.

Read the detailed description

This single center, prospective, randomised controlled clinical trial is designed to evaluate analgesic efficacy and opioid sparing effect of ultrasound guided paravertebral block (PVB) and external oblique intercostal (EOI) block versus systemic opioid based analgesia in adult patients undergoing elective laparoscopic cholecystectomy under general anesthesia.

Pain after laparoscopic cholecystectomy is often moderate to severe during the first 24 hours , and has somatic and visceral components . Regional approaches that target thoracoabdominal dermatomes and visceral afferents may provide superior analgesia, allow for earlier mobilisation, and reduce opioid-related adverse effects compared with intravenous opioid regimens alone. PVB provides unilateral segmental blockade at thoracic paravertebral level, while the EOI block deposits local anaesthetic in the fascial plane between the external oblique and intercostal muscles, with spread to relevant thoracoabdominal nerves.

In a parallel-group design, participants will be randomly allocated to bilateral thoracic PVB, bilateral EOI block or no truncal block with standard systemic analgesia. All regional blocks will be performed under ultrasound guidance after induction of general anaesthesia. Standardised volumes and concentrations of long-acting local anaesthetic will be used according to institutional practice. The control group will receive patient-controlled intravenous opioid analgesia as part of a multimodal approach.

Standardisation of intraoperative monitoring and technique of general anaesthesia according to departmental protocols will be done for perioperative anaesthetic management. Postoperative pain intensity will be assessed by an 11-point Numerical Rating Scale at specified time points during the first 24 hours. Rescue analgesia will be administered according to a predefined algorithm. The trial's purpose is to compare postoperative opioid use between groups and to investigate differences in pain trajectories and opioid-related adverse events in routine clinical conditions.

03

Conditions studied

  • Postoperative Pain
  • Laparoscopic Cholecystectomy
  • Paravertebral Block
  • External Oblique Intercostal Plane Block
  • Patient Controlled Analgesia

Keywords

  • Cholecystectomy
  • Pain
  • Analgesia
  • Tramadol
  • Nerve Block
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 65 years
  • Scheduled for elective laparoscopic cholecystectomy under general anesthesia
  • I-III
  • Able to understand the study procedure and provide

Exclusion criteria

Exclusion Criteria:

Patient refusal or inability to provide

Allergy or to local anesthetics, tramadol, or study medications

Coagulopathy or current anticoagulant therapy

Local infection at the planned block injection site

Severe hepatic or renal impairment

Chronic opioid use or opioid dependence

Neurological or psychiatric disorders affecting pain perception or communication

Pregnancy or breastfeeding

(BMI) > 35 kg/m²

Conversion to open cholecystectomy during surgery

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
151 participants (actual)

Study arms

  • Active comparator
    Paravertebral Block Group

    Participants in this arm will receive bilateral paravertebral block after induction of general anesthesia. Under ultrasound guidance, 0.25% bupivacaine (20 mL per side; total 40 mL) will be administered to provide postoperative analgesia following laparoscopic cholecystectomy. Patients will also receive standard intravenous paracetamol postoperatively.

    Procedure: Paravertebral Block (PVB)

  • Active comparator
    External Oblique Intercostal Block Group

    Participants in this arm will receive bilateral external oblique intercostal (EOI) block after induction of general anesthesia. Under ultrasound guidance, 0.25% bupivacaine (20 mL per side; total 40 mL) will be injected into the fascial plane between the external oblique and intercostal muscles. Standard intravenous paracetamol will be administered postoperatively.

    Procedure: External Oblique Intercostal Block (EOI Block)

  • Active comparator
    Control Group - IV PCA Tramadol

    Participants in this arm will receive intravenous patient-controlled analgesia (PCA) with tramadol for postoperative pain management. The PCA pump will be set to a maximum dose of 400 mg tramadol in 24 hours. Standard intravenous paracetamol (1 g every 8 hours) will also be administered. No regional anesthesia block will be performed in this group.

    Drug: Tramadol IV Patient-Controlled Analgesia (PCA)

Interventions

  • ProcedureParavertebral Block (PVB)

    Ultrasound-guided bilateral thoracic paravertebral block performed after induction of general anesthesia using 0.25% bupivacaine, 20 mL per side (total 40 mL).

  • ProcedureExternal Oblique Intercostal Block (EOI Block)

    Ultrasound-guided bilateral external oblique intercostal block performed after induction of general anesthesia with 0.25% bupivacaine, 20 mL per side (total 40 mL), injected between the external oblique and intercostal muscles.

  • DrugTramadol IV Patient-Controlled Analgesia (PCA)

    Intravenous patient-controlled analgesia (PCA) programmed to deliver tramadol with a maximum dose of 400 mg in 24 hours. Standard analgesia protocol includes IV paracetamol 1 g every 8 hours.

    Also known as: Control group

06

What researchers measure

Primary outcomes

  1. 24-hour postoperative tramadol consumption

    Total amount of intravenous tramadol administered via PCA within the first 24 hours after surgery.

    Time frame: Within the first 24 hours after surgery.

Secondary outcomes

  1. Postoperative pain scores at rest

    Postoperative pain intensity at rest will be assessed using the 11-point Numerical Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst imaginable pain), where higher scores indicate more severe pain.

    Time frame: 1, 6, 12, and 24 hours postoperatively

  2. Incidence of postoperative nausea and vomiting

    Presence of nausea and/or vomiting requiring antiemetic treatment.

    Time frame: Within 24 hours postoperatively

  3. Incidence of block-related complications

    Presence of complications related to the regional block (e.g., vascular puncture, pneumothorax, local anesthetic systemic toxicity).

    Time frame: Intraoperative and first 24 hours after block

  4. Patient satisfaction with analgesia

    Patient-reported satisfaction score for pain management (0 = very dissatisfied, 10 = very satisfied).

    Time frame: 24 hours postoperatively

07

Study locations

1 site
08

References and documents

Publications

  • Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11:S240-52. doi: 10.1002/acr.20543. No abstract available. PubMed 22588748 ↗
  • Erskine RN, White L. "A review of the external oblique intercostal plane block - a novel approach to analgesia for upper abdominal surgery". J Clin Anesth. 2022 Nov;82:110953. doi: 10.1016/j.jclinane.2022.110953. Epub 2022 Aug 19. No abstract available. PubMed 35994942 ↗
  • Hamilton DL, Manickam BP, Wilson MAJ, Abdel Meguid E. External oblique fascial plane block. Reg Anesth Pain Med. 2019 Jan 11:rapm-2018-100256. doi: 10.1136/rapm-2018-100256. Online ahead of print. No abstract available. PubMed 30635518 ↗
  • Hamilton DL, Manickam BP. Is a Thoracic Fascial Plane Block the Answer to Upper Abdominal Wall Analgesia? Reg Anesth Pain Med. 2018 Nov;43(8):891-892. doi: 10.1097/AAP.0000000000000838. No abstract available. PubMed 30339615 ↗
  • Kus A, Gurkan Y, Arslan ZI, Akgul AG, Aksu C, Toker K, Solak M. [Our ultrasound-guided paravertebral block experiences in thoracic surgery]. Agri. 2015;27(3):139-42. doi: 10.5505/agri.2015.59885. Turkish. PubMed 26356102 ↗
  • Barazanchi AWH, MacFater WS, Rahiri JL, Tutone S, Hill AG, Joshi GP; PROSPECT collaboration. Evidence-based management of pain after laparoscopic cholecystectomy: a PROSPECT review update. Br J Anaesth. 2018 Oct;121(4):787-803. doi: 10.1016/j.bja.2018.06.023. Epub 2018 Aug 7. PubMed 30236241 ↗
  • O'Donovan B, Martin B. The Novel Use of an External Oblique Nerve Catheter After Open Cholecystectomy. Cureus. 2021 Feb 26;13(2):e13580. doi: 10.7759/cureus.13580. PubMed 33796423 ↗
  • Alper I, Ulukaya S, Yuksel G, Uyar M, Balcioglu T. Laparoscopic cholecystectomy pain: effects of the combination of incisional and intraperitoneal levobupivacaine before or after surgery. Agri. 2014;26(3):107-12. doi: 10.5505/agri.2014.42650. PubMed 25205408 ↗
  • Shrestha BB, Lakhe G, Ghimire P. Postoperative Pain after Laparoscopic Cholecystectomy in a Tertiary Care Center: A Descriptive Cross-sectional Study. JNMA J Nepal Med Assoc. 2024 Jul 31;62(276):502-506. doi: 10.31729/jnma.8719. PubMed 39369396 ↗
  • De Cassai A, Sella N, Geraldini F, Tulgar S, Ahiskalioglu A, Dost B, Manfrin S, Karapinar YE, Paganini G, Beldagli M, Luoni V, Ordulu BBK, Boscolo A, Navalesi P. Single-shot regional anesthesia for laparoscopic cholecystectomies: a systematic review and network meta-analysis. Korean J Anesthesiol. 2023 Feb;76(1):34-46. doi: 10.4097/kja.22366. Epub 2022 Nov 8. PubMed 36345156 ↗

Individual participant data

Plan to share: Yes — Individual participant data (IPD) that underlie the results reported in publications (de-identified dataset including primary and secondary outcome variables) will be shared. No information that could identify participants will be included. Data dictionaries and statistical codes may also be made available upon reasonable request for academic and research purposes. Access will be granted after publication and following institutional data-sharing agreements.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: De-identified individual participant data will be available beginning 6-12 months after publication of the primary results and for a period of up to 3 years thereafter.

Access criteria: Researchers seeking access to the data will be required to submit a methodologically sound proposal and sign a data-use agreement to ensure confidentiality and compliance with ethical standards. Requests will be evaluated by the study investigators and relevant institutional authorities.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2025 to primary completion in Nov 2026, 11 months.

Of 2,113 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's 11 months is close to that.

Counting every sponsor, half of 2,126 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

Completion moved once since we started tracking on Sep 25, 2026: Dec 2026 → Nov 2026, on Nov 19, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2025
First posted
Nov 21, 2025
StartActual
Dec 1, 2025
Primary completionActual
Nov 17, 2026
CompletionActual
Nov 18, 2026was Dec 2026
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 19, 2026
Primary completion
Nov 1, 2026→Nov 17, 2026 (actual)
Nov 19, 2026
Study completion
Dec 5, 2026→Nov 18, 2026 (actual)
Nov 19, 2026
Enrollment
147 (estimated)→151 (actual)
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Recruiting→Completed
    Primary completion Nov 1, 2026→Nov 17, 2026 (now actual)
    Study completion Dec 5, 2026→Nov 18, 2026 (now actual)
    Enrollment 147 (estimated)→151 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07241949
Responsible party
Nurefsan Sadikoglu (Attending Specialist, Cukurova University) — Principal investigator
First posted
Nov 21, 2025
Start date
Dec 1, 2025
Primary completion
Nov 17, 2026
Completion
Nov 18, 2026
Last update
Nov 19, 2026

Study contacts

Nurefsan Sadikoglu, MD
principal investigator · Cukurova University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion